<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4737">
  <stage>Registered</stage>
  <submitdate>3/12/2014</submitdate>
  <approvaldate>3/12/2014</approvaldate>
  <nctid>NCT02314247</nctid>
  <trial_identification>
    <studytitle>Efficacy &amp; Safety Study of Selinexor in Relapsed/Refractory Peripheral T-cell Lymphoma &amp; Cutaneous T-cell Lymphoma</studytitle>
    <scientifictitle>Multi-center, Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KCP-330-013</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral T-cell Lymphoma (PTCL)</healthcondition>
    <healthcondition>Cutaneous T-cell Lymphoma (CTCL)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Selinexor

Experimental: Selinexor - 60 mg dose (equivalent to ~35 mg/m2)


Treatment: drugs: Selinexor
20 mg oral tablets: Oral 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle. Number of Cycles: up to 12 but there is no maximal duration for treatment.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  ECOG performance status of =2

          -  Relapsed or refractory disease to at least one prior systemic regimen.

          -  Measurable disease: according to IWC for all PTCL and according to CTCL Response in
             Skin consensus criteria for all CTCL patients

          -  Objective, documented evidence of disease progression on study entry</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known active central nervous system (CNS) lymphoma

          -  Active graft-versus-host disease after allogeneic stem cell transplantation. At least
             4 months must have elapsed since completion of allogeneic stem cell transplantation

          -  Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
             gastrointestinal function.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>16</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Concord Hospital - Concord</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Cabrini Hospital - Malvern</hospital>
    <postcode>2139 - Concord</postcode>
    <postcode>2139 - St. Leonards</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode> - Malvern</postcode>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Karyopharm Therapeutics Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a single-arm, multi-center, open-label Phase II study of the SINE compound Selinexor
      given orally to patients with relapsed/refractory PTCL and CTCL.

      Approximately 60 patients with relapsed or refractory PTCL and CTCL who meet the eligibility
      criteria and have none of the exclusion criteria will be enrolled to receive Selinexor until
      either disease progression or intolerance has occurred.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02314247</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Kauffman, MD, PhD</name>
      <address>Karyopharm Therapeutics Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>